Skip to main content

DUPIXENT is indicated as an add-on maintenance treatment of adult patients with inadequately controlled
chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm.

Not actual
DUPIXENT patients.

GIVE YOUR COPD
PATIENTS THE
OPPORTUNITY FOR
More I can moments

 
 
 
November is COPD Awareness Month

IT'S TIME TO THINK BEYOND EXACERBATIONS FOR YOUR APPROPRIATE COPD PATIENTS         

Reducing exacerbations is only part of the picture. Only DUPIXENT helps appropriate COPD patients experience benefits across 3 outcomes that can make a meaningful difference: fewer exacerbations, better breathing, and improved quality of life.1

EXPLORE THE DATA

US.DUP.26.09.0179  10/2026

DUPIXENT is the only biologic that combines the ability to1-3:

Reduce
Exacerbations

Up to

34%

In NOTUS, annualized rate of moderate or severe exacerbations for DUPIXENT + triple therapy at Week 52 (0.86 exacerbations per year [n=470] vs 1.30 for placebo + triple therapy [n=465]. Rate ratio 0.66 (95% CI: 0.54, 0.82); P<0.001; primary endpoint)1,a

In BOREAS, 30% reduction (0.78 vs 1.10) in moderate or severe exacerbations for DUPIXENT + triple therapy (n=468) vs placebo + triple therapy (n=471) Rate ratio 0.70 (95% CI: 0.58, 0.86). P<0.001; primary endpoint1-3

LEARN MORE
ABOUT EXACERBATIONS

AND

Improve
Patients’ breathing and quality of life

Numerical improvement in
post-bronchodilator FEV1

BOREAS Trial
  • 158 mL numerical improvement for DUPIXENT + triple therapy (n=468) vs 84 mL for placebo + triple therapy (n=471) at Week 121

NOTUS Trial

  • 134 mL numerical improvement for DUPIXENT + triple therapy (n=470) vs 67 mL for placebo + triple therapy (n=465) at Week 121

Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.

Improvement in quality of life as measured by SGRQ1,2,4

BOREAS Trial

51% of patients reported a clinically meaningful (≥4-point) improvement in SGRQ scores at Week 52 with DUPIXENT + triple therapy vs 43% for placebo + triple therapy (N=939; OR: 1.44; 95% CI: 1.10, 1.89; P=0.009).

NOTUS Trial

  • 51% responder rate at Week 52 for subjects treated with DUPIXENT + triple therapy vs 47% for placebo + triple therapy (N=721; OR: 1.16; 95% CI: 0.86,1.58)1,6

NOTUS results are descriptive. Definitive conclusions cannot be made.

DISCOVER QoL DATA

AND

Target
TWO OF THE KEY DRIVERS OF TYPE 2 INFLAMMATION

IL-4 and IL-13 are two of the key drivers of local and systemic inflammation1

The mechanism of dupilumab action has not been definitively established.1

EXPLORE THE MOA

  • The most common adverse reactions (incidence ≥2%) are viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reaction, rhinitis, eosinophilia, toothache, and gastritis1
  • aModerate exacerbations were exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were exacerbations that led to hospitalization or an emergency department visit or that resulted in death.1-3

Post Hoc Data on COPD Exacerbations Leading to Hospital Visits Now Available

Explore the data
  • BOREAS Trial 30% reduction in the annualized rate of moderate or severe exacerbations for DUPIXENT + triple therapy (0.78 exacerbations per year [n=468] vs 1.10 for placebo + triple therapy [n=471]; rate ratio: 0.70 [95% CI: 0.58, 0.86] P<0.001)a
  • NOTUS Trial 34% reduction in the annualized rate of moderate or severe exacerbations for DUPIXENT + triple therapy (0.86 exacerbations per year [n=470] vs 1.30 for placebo + triple therapy [n=465]; rate ratio: 0.66 [95% CI: 0.54, 0.82] P<0.001)a

Number needed to treat (NNT):

Based on pooled analysis of BOREAS and NOTUS

For every

3 patients
on DUPIXENT,

Patients

1 moderate or severe
exacerbation was prevented5

  • The annualized rate of moderate or severe exacerbations for the DUPIXENT and placebo arms in the pooled analysis was 0.794 and 1.156, respectively (rate ratio 0.687, 95% CI 0.595, 0.793)

Definitive conclusions cannot be reached as the pre-specified pooled analysis was not controlled for multiplicity and the low exacerbation rate observed in the control group might limit the generalizability of our findings.

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; OR, odds ratio; QoL, quality of life; SGRQ, St George’s Respiratory Questionnaire.

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and
offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN HOW WE CAN HELP

DUPIXENT MyWay
ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.

contact a rep